申请人:Shen Wang
公开号:US20140128417A1
公开(公告)日:2014-05-08
The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
本发明提供了炔基取代喹唑啉化合物,例如式(I)化合物,它们是不可逆的ErbB激酶抑制剂。这些化合物在治疗ErbB激酶活性参与的疾病和紊乱(例如高增殖性紊乱,如癌症)方面非常有用。